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Objectives This study sought to assess clinical, angiographic, and intravascular ultrasound (IVUS) findings in patients devel-
oping coronary aneurysms (CANs) after drug-eluting stent (DES) implantation.
Background The long-term safety of DES remains unsettled.
Methods This study analyzed 1,197 consecutive patients with late angiographic evaluation after DES implantation. In 15
patients (1.25%, 95% confidence interval: 0.58 to 1.93), CANs developed at follow-up. Analyses included quanti-
tative angiography and volumetric IVUS.
Results DES developing CANs were more frequently implanted during acute myocardial infarction and were longer than
those without this outcome. The elapsed time from DES implantation to CAN diagnosis was 313  194 days.
Angiographically, maximal CAN diameter measured 5.1  1.2 mm. On IVUS, CAN external elastic lamina area
was 32  13.1 mm2 and incomplete apposition area was 12.1  8.6 mm2. Two patients presented with acute
myocardial infarction secondary to DES thrombosis. Four additional patients presented with unstable angina and
underwent CAN aggressive dilation (3 were also treated for concomitant in-stent restenosis). Dual antiplatelet
therapy was recommended in the remaining 9 patients who were asymptomatic at CAN diagnosis, but 1 of
them eventually died of cardiogenic shock after a CAN-related myocardial infarction. After a mean follow-up of
399  347 days, the 1-year event-free survival was 49  14% and was related to CAN size on IVUS. In 2 pa-
tients, CANs disappeared at repeated late angiography and IVUS showed abluminal CAN thrombosis.
Conclusions After DES implantation, CANs are rare and may be detected in asymptomatic patients. However, CANs are fre-
quently associated with adverse clinical events as a result of DES restenosis and DES thrombosis. Further stud-
ies are required to determine the implications of this distinct new entity. (J Am Coll Cardiol 2009;53:2053–60)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.069o
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fihe use of drug-eluting stents (DES) during coronary
nterventions has exploded in recent years because of their
ramatic ability to inhibit neointimal proliferation (1–3).
owever, DES may affect the normal healing process of the
essel wall after vascular injury, resulting in delayed endo-
helization (4,5), and currently, prolonged dual antiplatelet
herapy is recommended in these patients (6,7). Further-
ore, the pharmacological effects of DES may influence the
emodeling process and lead to late incomplete stent appo-
ition (8–11).
The appearance of angiographic coronary aneurysms
CANs) after coronary interventions is very rare (12). The
rom the Interventional Cardiology Unit, Cardiovascular Institute, Clı´nico San
arlos University Hospital, Madrid, Spain.D
Manuscript received August 11, 2008; revised manuscript received January 6, 2009,
ccepted January 12, 2009.ccurrence of angiographic CAN after DES has generated
reat interest but, to date, this finding has only been
arginally reported in large-scale clinical trials or described
n anecdotal case reports (13–16). Although CAN may
evelop as a result of exaggerated positive remodeling of the
essel wall (13–16), the underlying pathophysiology remains
nknown. In some patients, this phenomenon has been
inked to hypersensitivity reactions (15), bacterial arteritis
17–21), or other rare predisposing factors such as Kawasaki
isease (14). Finally, it has also been suggested that DES-
elated CAN might predispose to DES thrombosis (15,18).
urrently, however, the clinical implications of angio-
raphic CAN remain uncertain.
The aim of the present study was to systematically assess
linical, angiographic, and intravascular ultrasound (IVUS)
ndings in patients developing angiographic CAN after
ES implantation.
t
g
p
t
e
p
p
p
t
F
u
s
f
(
a
l
r
r
u
c
l
q
s
i
b
a
q
2
n
o
s
w
s
a
c
n
f
A
i
c
q
g
a
t
i
w
o
Q
w
4
i
r
n
I
d
(
q
w
v
s
Q
o
S
0
e
s
a
a
t
v
w
a
s
T
e
v
C
o
S
c
p
S
v
M
C
c
R
I
1
d
(
p
p
m
f
r
C
c
2054 Alfonso et al. JACC Vol. 53, No. 22, 2009
Coronary Aneurysms After DES Implantation June 2, 2009:2053–60Methods
Patient selection and study de-
sign. From the clinical and an-
giographic databases of the Car-
diovascular Institute, Clı´nico San
Carlos University Hospital (Ma-
drid, Spain), 1,197 consecutive
patients with late angiographic
evaluation after DES implanta-
ion were identified and analyzed. This represents an an-
iographic follow-up rate of 71% in the initial 1,685
atients treated with DES in our institution. Fifteen of
hese patients (1.25%) had CANs at repeated angiographic
valuation. Once the diagnosis of CAN was established,
atients were prospectively surveyed according to a specific
rotocol. The study was an investigator-driven initiative. All
atients gave written informed consent to the study protocol
hat was approved by the institutional ethical review board.
ollow-up and definitions. At our institution, patients
ndergoing DES implantation are routinely scheduled for a
tress test and angiographic evaluation at 9-month
ollow-up or earlier if clinically indicated. Clopidogrel
75 mg/day) was maintained for 9 months. However, in
symptomatic patients with a negative exercise test result,
ate angiography may be halted if this is requested by the
eferring physician. By protocol, however, all patients with
ecurrent symptoms or with objective evidence of ischemia
ndergo late angiographic evaluation.
Continuous, prospective, clinical surveillance was indi-
ated in all patients with the diagnosis of CAN to assess
ong-term outcomes. A pre-defined, structured, detailed
uestionnaire was used. Major events were verified against
ource documentation. Clinical events (death, myocardial
nfarction, target vessel revascularization) were adjudicated
y personnel unaware of the intervention results and late
ngiographic findings. Myocardial infarction diagnosis re-
uired 2 of the following: 1) prolonged (30 min) chest pain;
) a creatine kinase increase greater than twice the upper
ormal value (with abnormal MB fraction); and 3) appearance
f new pathological Q waves. The Academic Research Con-
ortium definition of definitive or probable stent thrombosis
as used (2). Hypersensitivity reactions were specifically
ought in every patient including dermatological reactions,
naphylaxis, arthralgia, and fever. Finally, laboratory tests with
omplete blood cell counts (including eosinophils) and immu-
oglobulin E titres were performed at CAN diagnosis and at
ollow-up.
ngiographic analysis. Coronary angiograms (baseline,
ntervention, follow-up) were carefully analyzed by dedi-
ated personnel at an angiographic core laboratory. On
ualitative analysis, CAN was defined as a localized angio-
raphic dilation of the vessel lumen (50% larger than the
djacent reference vessel) at late angiography, closely related
o the underlying DES or its edges, that was not present
Abbreviations
and Acronyms
CAN  coronary aneurysm
CI  confidence interval
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasoundmmediately after the procedure (12). Particular attention aas taken to identify dissections or extravasation suggestive
f contained perforations during the initial intervention.
uantitative coronary angiographic analysis was performed
ith an automatic edge-detection system (MEDIS, CMS
.0, Leiden, the Netherlands). The angiographic analysis
ncluded the treated segment (lesion site  the treated
egion  the adjacent [5-mm] vessel on each side). Reste-
osis was defined as 50% diameter stenosis at follow-up.
VUS. All IVUS studies (30/40-MHz mechanical trans-
ucers) were performed using an automated pullback system
0.5 mm/s) and recorded on sVHS videotapes for subse-
uent off-line analysis (22,23). Incomplete DES apposition
as defined as 1 stent strut clearly separated from the
essel wall, with blood speckling behind it, in a vessel
egment not encompassing a side-branch exit (8–11).
uantitative IVUS analyses were performed using a previ-
usly validated automatic contour detection system (Echo-
can, Tomtec, Germany) (22,23). Diameters, areas (every
.3 mm of DES length), and volumes of lumen, stent, and
xternal elastic lamina were measured. Subsequently, at the
egment with incomplete apposition, care was taken to
nalyze the lumen outside the stent and the maximal depth,
rea, length, and volume of this lumen. The lumen outside
he stent was considered to be part of the effective total
essel lumen (8–11). The extent of incomplete apposition
as further evaluated by measuring the arc of malapposition
nd the number of nonapposed DES struts (8–11). Images
uggestive of partial thrombosis of this space were analyzed.
he volume of plaque behind the stent was calculated as the
xternal elastic lamina volume minus the sum of the DES
olume and the lumen outside the stent volume. On IVUS,
AN was defined as a maximal effective lumen area 50%
f reference lumen area (8–11).
tatistical analysis. Data are presented as values and per-
entages or mean  SD. Categorical variables were com-
ared with the chi-square test or the Fisher exact test. The
tudent t test was used for the comparison of continuous
ariables. Event-free survival was estimated by Kaplan-
eier analysis. The SPSS package version 12.0 (SPSS Inc.,
hicago, Illinois) was used. A p value of 0.05 was
onsidered statistically significant.
esults
nitial procedural findings. Baseline characteristics of the
5 patients in whom angiographic CANs developed (inci-
ence 1.25%, 95% confidence interval [CI]: 0.58 to 1.93)
Fig. 1) and of the remaining 1,182 cases without CAN are
resented in Table 1. Patients who develop CAN had initial
rocedures more frequently performed during an acute
yocardial infarction and in occluded vessels, and more
requently required long DES and multiple DES and had
esidual dissections as compared with patients in whom
AN did not develop (Table 1). One of these patients had
hronic myeloid leukemia, 1 had lung carcinoma, and
nother required prior surgery for bladder cancer.
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June 2, 2009:2053–60 Coronary Aneurysms After DES ImplantationDuring the initial interventions 1 CAN patient suffered
rom abdominal sepsis, and another, with acquired immu-
odeficiency syndrome that had withheld the antiretroviral
herapy, presented a prolonged episode of fever of unknown
tiology. Both patients eventually responded to antibiotic
herapy. Two asthmatic patients suffered from bronchos-
asm crisis that resolved with conventional management.
owever, no additional patient developing CAN presented
ith signs of infection or allergic reaction, or had fever,
eukocytosis, or hypereosinophilia during initial admission.
AN diagnosis. The elapsed time from DES implantation
o CAN diagnosis was 313  194 days. Two patients with
ANs presented with large acute myocardial infarctions as
result of DES thrombosis (633 and 727 days after DES
mplantation, both on aspirin alone). In the first patient,
rimary angioplasty required the use of aggressive balloon
ilation of the proximal CAN to obtain angiographic
uccess. However, this patient had an advanced lung carci-
oma and died suddenly (without chest pain or electrocar-
iographic changes) 48 h later. Autopsy examination could
ot be obtained. In the second, angiographic evidence of
ES thrombosis was obtained 24 h after the infarction, and
uring an elective repeated intervention, residual an-
iographic CAN persisted (although reduced in size) de-
pite aggressive balloon dilation and additional DES im-
Patient # 2ti t  
Patient # 10ti t  
Patient # 4ti t  
Pre tsoP
Figure 1 Angiographic Images of 3 Coronary Aneurysms After D
(Left) Before intervention (pre); (middle) after drug-eluting stent implantation (poslantation. rFour additional patients presented with unstable angina
t the time of CAN diagnosis. Three of them, with CANs
ocated in the proximal part of the DES, also had concom-
tant severe distal-edge in-stent restenosis. In these 3
atients the distal DES restenosis was treated with repeated
ES implantation, whereas the proximal CAN underwent
ggressive balloon angioplasty in an attempt to appose the
tent to the vessel wall. The fourth patient presented with a
AN on the left anterior descending coronary artery but
ad no significant stenosis. A CAN-related distal emboli-
ation was suspected because of recurrent angina associated
ith troponin elevation and negative T waves on the
nterior leads, and eventually aggressive CAN balloon
ngioplasty was successfully performed. In these 6 patients
ith CANs requiring reintervention, larger balloon diameters
3.75  0.5 mm vs. 3.0  0.5 mm, p  0.05) were used as
ompared with those used at initial DES implantation.
The remaining 9 patients were asymptomatic and had
egative exercise test results at CAN diagnosis. In all of these
ases, CANs were incidental findings detected in a scheduled
outine angiographic evaluation and lifelong dual antiplatelet
herapy was recommended. After 445  345 days of follow-
p, 8 patients remained asymptomatic and event free. How-
ver, 1 patient withheld clopidogrel therapy and died (243 days
fter diagnosis) of cardiogenic shock secondary to a CAN-
elated large acute anterior myocardial infarction, probably as a
sisongaiD
luting Stent Implantation
ht) at late follow-up, when coronary aneurysms (white arrows) were diagnosed.rug-E
t); (rigesult of DES thrombosis (Table 2). Figure 2 shows the clinical
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Coronary Aneurysms After DES Implantation June 2, 2009:2053–60utcome (mean follow-up 399 347 days) for the entire series
f patients.
At the time of CAN diagnosis and at late clinical
ollow-up, no patient presented with fever, signs of infec-
ion, or allergic reactions. Except for the patient with
hronic myeloid leukemia, none of them had leukocytosis
leukocytes 9.430  3.600/l; 64  18% neutrophils),
ypereosinophilia (1.45  1.28%), or abnormal immuno-
lobulin E titres (37  21 IU/ml) during the study period.
ngiographic and IVUS findings. Angiographic data before
nd after initial DES implantation and at the time of CAN
iagnosis are presented in Tables 1 and 2. Angiographically,
he mean maximal CAN diameter was 5.1  1.2 mm. Five
ANs were located in the proximal third and 10 in the mid
ES segment (including 4 patients with overlapping DES).
ngiographically, 10 CANs were classified as saccular, 1 as
usiform, and 4 as complex/multilobulated.
IVUS studies were obtained in 13 patients (Fig. 3). All
ngiographic CANs also fulfilled the IVUS definition of
aseline Clinical, Angiographic,nd Procedural Characte istics athe Tim of Initial DES Implantation
Table 1
Baseline Clinical, Angiographic,
and Procedural Characteristics at
the Time of Initial DES Implantation
CAN
(n  15)
No CAN
(n  1,182) p Value
Age (yrs) 58 11 63 11 0.85
Female sex 3 (20) 278 (23) 1.00
Risk factors
Diabetes mellitus 6 (40) 487 (41) 0.92
Hyperlipidemia 9 (60) 726 (61) 0.91
Hypertension 11 (73) 729 (63) 0.39
Ever smoked 12 (80) 733 (62) 0.15
Clinical features
AMI 6 (40) 179 (15) 0.02
Unstable angina 4 (26) 631 (53)
Stable angina 5 (34) 372 (32)
Previous myocardial infarction 3 (20) 492 (42) 0.09
Ejection fraction (%) 57 11 64 13 0.19
Angiographic data, lesions 15 1,566
LAD 11 (73) 764 (49) 0.27
LCX 2 (13) 293 (19)
RCA 2 (13) 434 (28)
Total occlusion 4 (27) 192 (12) 0.10
B2C lesion 8 (57) 1,114 (71) 0.25
Procedural characteristics
DES type (SES/PES/other) 5/10/0 637/768/160 0.26
DES length (mm) 26.8 11 20.8 10 0.02
Multiple DES (%) 4 (27) 139 (9) 0.04
Maximal pressure (atm) 16.4 2.4 16.1 2.8 0.68
Maximal balloon diameter (mm) 3.1 0.5 3.0 0.4 0.55
Residual dissection (%) 4 (27) 47 (3) 0.001
Reference vessel (mm) 2.75 0.5 —
Balloon/artery ratio 1.13 0.1 —
alues are mean  SD or n (%).
  not available; AMI  acute myocardial infarction; CAN  coronary aneurysm; DES 
rug-eluting stent(s); LAD  left anterior descending coronary artery; LCX  left circumflex
oronary artery; PES  paclitaxel-eluting stent(s); RCA  right coronary artery; SES  sirolimus-
luting stent(s).neurysm. In all cases, IVUS readily detected malapposition Cl
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June 2, 2009:2053–60 Coronary Aneurysms After DES Implantationith a prominent distance between the DES struts and the
essel wall. The extent of incomplete apposition (length,
ean and maximal area, and volume) and other relevant
VUS features are summarized in Table 3. In the 6 patients
ho underwent repeated interventions, maximal area of
0 1 2 3 4 5 6 7 8 9 10 11 12
0
20
40
60
80
100
58%
49%
87%
77%
(%)
Time (months)
Freedom from Death, MI
Freedom from Death, MI, TVR
Figure 2 Event-Free Survival Estimates
After the Diagnosis of Coronary Aneurysms
At 1 year, freedom from death or myocardial infarction (MI) was 77  12% (95%
confidence interval: 54% to 100%) and freedom from death, MI or target vessel
revascularization (TVR) was 49  14% (95% confidence interval: 22% to 76%).
Patient # 5ti t  
A
C
Figure 3 Intravascular Ultrasound Images of a Coronary Aneury
(A) Angiographic image of a coronary aneurysm in the left anterior descending corona
incomplete apposition of the stent struts (arrows). (C) Longitudinal reconstruction ofncomplete apposition (11.6  3 mm2 vs. 5.5  0.6 mm2,
 0.05) was significantly reduced after treatment.
Angiographically, CAN size was similar in the 3 patients
uffering DES thrombosis as compared with patients with-
ut this event. On IVUS, however, patients with DES
hrombosis had significantly larger CANs as compared with
atients without DES thrombosis (Table 4). Further, event-
ree survival was also better in patients with smaller CANs
n IVUS (Table 4). During additional follow-up, sponta-
eous abluminal CAN thrombosis was suspected on re-
eated angiography and confirmed with IVUS in 2 patients.
iscussion
he main findings of our study are as follows: 1) CANs are
arely detected (1.25%) after DES implantation; 2) coronary
ngiography is able to provide an accurate diagnosis of this
ntity; 3) IVUS provides further anatomic insights, includ-
ng the extent of DES malapposition, which seems to have
ajor prognostic implications; 4) CAN may be detected in
symptomatic patients who have good long-term clinical out-
ome on an indefinite dual antiplatelet regimen; 5) however,
AN may be associated with DES restenosis, and different
epeated interventions are required to address these distinct
ntities; and 6) CAN may also present as DES thrombosis.
Major attention recently has been focused on late com-
lications after DES implantation (8–21). The present
B
y (arrow). (B) Intravascular ultrasound image showing the aneurysm with severe
sel disclosing the aneurysm and the full extent of malapposition (arrows).sm
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Coronary Aneurysms After DES Implantation June 2, 2009:2053–60eport represents the first systematic study to provide a
omprehensive assessment of patients in whom angio-
raphic CAN develops after DES implantation. Previous
tudies have only reported anecdotal descriptions of angio-
raphic CAN after DES, either from large-scale clinical
rials or as case-report descriptions (12–16). In these scarce
eports, outcome has ranged from asymptomatic patients,
ith CAN representing just an incidental angiographic
nding without clinical consequences, to CAN associated
ith DES thrombosis (15,18). In the TAXUS VI trial (24),
nvolving long and complex lesions, in 1.4% of patients in
he paclitaxel-eluting stent arm late acquired aneurysms
eveloped (vs. 0.5% in the bare-metal stent group, p 0.62)
ut no additional information was provided on these pa-
ients. In a recent letter to the editor, Bavry et al. (16)
escribed preliminary findings of 4 patients with angio-
raphic CANs after DES implantation. Two patients were
anaged conservatively and, on continued clinical surveil-
ance, 1 evolved to CAN resolution. Two patients had
uccessful intervention: 1 with percutaneous coiling and 1 by
urgical excision and coronary bypass grafting; interestingly
nough, pathological examination in the latter patient
howed eosinophilic infiltration of the vessel wall (16).
Although the underlying mechanism for CAN develop-
ent remains unknown, several hypotheses may be postu-
ated. Extensive acute vessel damage during the initial
rocedure, hypersensitivity reactions, infectious processes,
nd phenomena resembling extreme cases of late acquired
alapposition may all be implicated.
cute deep vessel wall injury. Early CAN development may
e a consequence of mechanical problems resulting from
omplicated procedures, large dissections, contained perfora-
ntravascular Ultrasoundinding of Coron ry Aneurysms
Table 3 Intravascular UltrasoundFindings of Coronary Aneurysms
EEL mean area (mm2) 26.7 9.7
EEL maximal area (mm2) 32.0 13.1
EEL volume (mm3) 303.7 194.9
DES mean area (mm2) 7.6 2.0
DES minimal area (mm2) 6.6 1.8
DES maximal area (mm2) 8.8 2.4
DES volume (mm3) 70.6 42.6
Plaque behind DES mean area (mm2) 12.8 5.8
Plaque behind DES maximal area (mm2) 17.5 8.1
Plaque behind DES volume (mm3) 169.9 144.8
ISA mean area (mm2) 7.0 4.8
ISA maximal area (mm2) 12.1 8.6
ISA volume (mm3) 76.2 68.4
Effective (total) maximal lumen area (mm2) 19.8 9.6
Effective (total) lumen volume (mm3) 135.1 97.9
ISA maximal depth (mm) (strut-CAN wall) 2.2 0.8
Number of struts with ISA 4.5 1.3
ISA maximal arc (angle °) 135 59
ISA length (mm) 9.2 4.2
ISA partial thrombosis 3
EL  external elastic lamina; ISA incomplete stent apposition; other abbreviations as in Table 1.ions, or even vessel ruptures (12). In these patients, pseudo- oneurysms may actually develop rather than true CANs, and
his rare substrate has been previously shown after various
oronary interventions (12). Notably, acute eosinophilic infil-
rates at the vessel wall have been identified in patients suffering
rom coronary dissections (17). In this complicated setting,
ES implantation might impair the normal healing process of
he vessel wall (25,26), favoring CAN development. Interest-
ngly, systemic anti-inflammatory agents also seem to predis-
ose to CAN formation (27). In our series, procedural-related
ajor dissections were detected in 5 patients (4 patients had
esidual dissections after the procedure). Further, total vessel
cclusion, which may also predispose to wall disruption as a
esult of subintimal wire advancement, was present in 4 cases.
owever, particularly aggressive interventions (pressures or bal-
oon to artery ratios) were not identified in our patients. Finally,
he potential influence of concurrent neoplasia or acquired immu-
odeficiency syndrome, on vessel wall healing, remains to be
efined.
ypersensitivity reactions. Virmani et al. (15) demon-
trated localized hypersensitivity vasculitis, with accumula-
ion of T-lymphocytes and intense eosinophilia, in a patient
ho eventually died of late DES thrombosis. Lack of
ndothelial coverage and severe DES malapposition caused
y aneurysmal vessel enlargement was shown. Hypersensitivity
eaction was thought to be caused by the polymer (16).
ikewise, high-intensity uptake of gallium localized at the site
f previously implanted DES also has been reported (28).
Alternatively, a generalized hypersensitivity reaction has
een suggested in some patients suffering from DES throm-
osis. The RADAR (Research on Adverse Drug events
nd Reports) study (29) showed 17 distinct cases of
ypersensitivity or systemic allergic reactions “probably or
ertainly” related to the DES. Clinical manifestations were
rimarily cutaneous and usually begun within 2 weeks of
ES implantation. Notably, 4 of these patients presented
ES thrombosis, and autopsy studies confirmed intra-DES
osinophilic inflammation and lack of intimal healing. No
atient in our series, however, had documented hypersen-
itivity reactions after the procedure.
VUS Data of Coronaryneurysm Accordi g to Clinical Outcome
Table 4 IVUS Data of CoronaryAneurysm According to Clinical Outcome
Clinical Outcome Event No Event p Value
DES thrombosis* n  3 n  10
Angiographic CAN diameter (mm) 4.5 0.7 5.2 1.3 0.36
IVUS EEL volume (mm3) 504.5 145 243.4 168.9 0.035
IVUS ISA volume (mm3) 168.2 84.6 48.6 31.5 0.002
IVUS effective lumen volume (mm3) 271.8 104.4 94.1 47.7 0.001
Any event† n  7 n  6
Angiographic CAN diameter (mm) 4.8 1.2 5.3 1.2 0.48
IVUS EEL volume (mm3) 405.3 201.3 184.9 105.8 0.035
IVUS ISA volume (mm3) 100.1 81.9 48.4 38.3 0.18
IVUS effective lumen volume (mm3) 167.3 116.1 97.7 60.9 0.21
Definitive or probable thrombosis according to the Academic Research Consortium definition.
Events include death, myocardial infarction, and target vessel revascularization.
EEL external elastic lamina; ISA incomplete stent apposition; IVUS intravascular ultrasound;
ther abbreviations as in Table 1.
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June 2, 2009:2053–60 Coronary Aneurysms After DES ImplantationIn-stent restenosis has also been associated with allergies
o metals such as nickel, molybdenum, and chromium (15),
ut the potential relationship between allergies to metals
nd CAN formation or stent thrombosis has not been
onfirmed. In 4 patients of the present series both CAN and
n-stent restenosis concomitantly developed, although at
eparate DES locations.
ocal infection. Some investigators have reported the ex-
eedingly rare occurrence of mycotic CANs or coronary
seudoaneurysms after DES implantation (17–21). It has
een suggested that local DES infection may result from
irect contamination of the device at the time of delivery or
rom subsequent bacteremia. DES might constitute a po-
entially predisposing factor by blunting the local inflam-
atory response of the vessel wall, favoring the maintenance
r extension of the infection (17). The immunosuppressive
ctivity of DES could be implicated. In most cases Staph-
lococcus aureus infections have been shown (17–21). These
atients typically present with fever and systemic manifes-
ations, including septicemia, and a clinical picture of
ulminant infection with poor prognosis. In our series, 2
atients suffered infectious processes with subsequent sepsis
uring initial DES procedures but (apparently) responded
ell to antibiotics with complete initial resolution.
essel remodeling and DES malapposition. This phe-
omenon seems to be more frequent after DES than after
are-metal stent implantation (7–11). Predictors of late-
cquired malapposition include DES implantation in acute
oronary syndromes, long lesions, and chronic occlusions
8,10). The MISSION study (30) suggested that after
rimary angioplasty, late malapposition may be recognized
n up 37% of patients treated with DES. Interestingly, in 6
f our patients (40%) DES were initially implanted during
n acute myocardial infarction. In our series, CANs were
lso more frequently detected after long and multiple DES
mplantations. Finally, 4 CANs emerged from areas of DES
verlap. This may suggest that, in some patients, CAN
ould be related to excessive vessel remodeling as a result of
igh drug concentrations. The appearance of angiographic
AN has been noticed in anecdotal patients serially followed
p for IVUS-detected incomplete DES apposition (7–10). It
ould be speculated that vessel dilation may beg for further
essel dilation, and eventually, angiographically visible CAN
ormation. In addition, it has been suggested that late malap-
osition might provide a nidus for thrombus formation (23).
espite its worrisome appearance, most studies suggest that
ate malapposition represents a pure IVUS finding without
linical repercussions (8–11). Nevertheless, recent reports
31,32) suggested that incomplete apposition may indeed
onstitute a risk factor for late DES thrombosis.
linical implications. Currently, the natural history and
he therapy of choice for patients in whom CAN develops
emains unknown. Furthermore, it is still unclear whether
ES are more prone to develop this complication than
are-metal stents (24). Our findings indicate that CAN may
epresent just incidental angiographic findings in asymp- Domatic patients. In these cases, a continuous clinical sur-
eillance under prolonged dual antiplatelet therapy might be
ndicated, providing compliance is guaranteed. This strategy
s further supported by the possibility of CAN spontaneous
esolution (16), as confirmed in 2 patients in the present
tudy. Longer periods of follow-up are required to fully
issipate risk concerns in asymptomatic patients receiving a
orrect dual antiplatelet regimen.
However, our findings underscore that CAN may also lead
o serious, potentially life-threatening clinical problems, in-
luding DES thrombosis and death. In our series, this was
lways related to discontinuation of dual antiplatelet therapy.
f interest, our findings also suggest that in patients with
AN, IVUS may be useful to identify those at higher risk.
atients with larger total vessel areas and larger areas of
alapposition had poorer prognosis. Therefore, the fate of
AN seems to depend on its size, and in this regard, IVUS
ppears to be superior to angiography. Overall, the natural
istory of our patients was poor, suggesting that aggressive
trategies should be contemplated, especially in patients with
arge CAN.
Lack of neointimal coverage of DES struts, severe malap-
osition, and rheologic factors may be implicated in the risk of
AN thrombosis. In these cases an aggressive approach
balloon overdilation, coiling, covered stents, or surgical exci-
ion) (16) seem justified to prevent this devastating complica-
ion. Currently, the challenge remains to differentiate high-risk
ANs versus those associated with a benign outcome. In fact,
bluminal CAN thrombosis may constitute a double-edged
word leading to complete CAN resolution in some patients
ut increasing the risk of DES thrombosis in others. Serial
tudies are required to provide mechanistic underpinnings for
AN development and related complications.
tudy limitations. First, our series, despite including the
argest number of patients reported to date, remains very
mall. Therefore, caution is required when analyzing poten-
ial predictors of this rare complication, and especially,
redictors of adverse clinical events. In this regard, our
ndings should be just considered hypothesis generating
nd should be confirmed in larger series of patients. Second,
espite our systematic attempt to obtain routine late an-
iography in this real-world patient population, eventually
his information was not obtained in all patients, and this
ight affect our incidence estimates. Third, a control group
f patients systematically followed up after bare-metal stent
mplantation (to compare incidence and implications of
AN) would have been of interest.
onclusions
evelopment of CAN after DES implantation is rare. This
nique phenomenon is usually detected in asymptomatic
atients and has a benign clinical course under a dual-
ntiplatelet regimen. However, angiographic CAN may be
ssociated with DES restenosis, and more importantly, with
ES thrombosis. Intravascular ultrasound seems to be
u
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Coronary Aneurysms After DES Implantation June 2, 2009:2053–60seful for identifying patients at higher risk for complica-
ions. Additional studies are required to identify patients at
isk for adverse events and also to determine the most
easonable intervention for this challenging new entity.
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